Sp131
INTERPRETING MANOMETRY IN THE PATIENT WITH ALTERED ANATOMY
Date
May 18, 2024
Explore related products in the following collection:
Presenter
Amsterdam UMC, University of Amsterdam
Tracks
Related Products
Improving our Understanding in Pathogenesis and Therapeutics in Eosinophilic Esophagitis
SOCIETY: AGA Pathophysiologic advances with management implications in eosinophilic esophagitis
EFFICACY AND SAFETY OF THE SELECTIVE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD, IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS OVER 52 WEEKS IN THE PHASE 2 VOYAGE STUDY
BACKGROUND: Etrasimod is an investigational, oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator in development to treat immune-mediated inflammatory disorders…
CALY-002, AN ANTI-IL-15 ANTIBODY, RESULTS IN HISTOLOGICAL AND CLINICAL IMPROVEMENT IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS IN A PHASE 1A/B STUDY
Interleukin-15 (IL-15) is a cytokine involved in tissue homeostasis and inflammation, and a potent regulator of innate and adaptive immune responses. IL-15 expression has been shown to be dysregulated in eosinophilic esophagitis (EoE)…
DEVELOPMENT OF A DIGITAL PATHOLOGY ANALYSIS ALGORITHM TO AUGMENT QUANTIFICATION OF PEAK EOSINOPHIL COUNT IN BIOPSIES FROM PATIENTS WITH EOSINOPHILIC ESOPHAGITIS
BACKGROUND: Eosinophil infiltration is a hallmark of eosinophilic esophagitis (EoE). Histologic assessment of esophageal biopsies is required for diagnosis and evaluation of treatment effect. Current diagnostic criteria are based mainly upon a peak eosinophil count (PEC) ≥15…
